Published: May, 2017
With several companies actively working toward the development of effective drugs and treatments to cure dilated cardiomyopathy, the competitive spirit between the market players will grow, notes Transparency Market Research (TMR). For instance, in February 2017, MyoKardia, Inc., a biopharmaceutical company initiating innovative precision medicine solutions, announced that the first batch of healthy subjects were administered with MYK-491. MYK-491 is a treatment for dilated cardiomyopathy which is in its Phase I. With regards to competition, the global dilated cardiomyopathy therapeutics market is fragmented.
A number of companies are establishing collaborations, mergers, and acquisitions. For instance, in January 2015, leading player Array BioPharma made an announcement related to its plans of acquiring a late stage oncology product, worldwide rights to encorafenib, from another strong player, Novartis Pharma AG.
The global market for dilated cardiomyopathy therapeutics is expected to reach US$328.6 mn by 2020, according to the findings of TMR. The market will display a CAGR of 4.6% between the forecast period 2014 and 2020, finds the report.
Rising Patient Population Prompts Adoption of Dilated Cardiomyopathy Therapeutics
The angiotensin II receptor blockers surfaced as the leading segment by drug class in the global market for dilated cardiomyopathy therapeutics in 2013. This segment was followed by beta blockers. The growing adoption of angiotensin II receptor blockers can be attributed to the high degree of acceptance of these drugs due to their superior effectiveness. By geography, North America led the global market for dilated cardiomyopathy therapeutics in 2013. High prevalence of cardiac diseases is driving the growth of this region. Asia Pacific is waiting in the wings to displace North America, as its growing healthcare infrastructure and massive patient population propels growth of the market for dilated cardiomyopathy therapeutics.
Alarming Incidence of Heart Diseases Propels Demand
The alarming rise in the frequency of heart failure and other cardiac disorders is one of the most prominent growth drivers of the global market for dilated cardiomyopathy therapeutics. Dilated cardiomyopathy is responsible for about 30 to 40% of the total number of congestive heart failures every year. The World Health Organization (WHO) estimated the number of deaths attributed to heart disorders at 17.5 million in 2013. The rising incidence of congestive heart failure worldwide has created a pressing need for effective drugs and treatments, boosting the market for cardiomyopathy therapeutics.
A number of studies reveal that angiotensin receptor blockers, for instance, valsartan, can bring down the frequency of hospitalization by 28%. In patients suffering from systolic heart failure, there was a reduction by almost 37% in deaths as well as hospitalizations due to advanced dilated cardiomyopathy therapeutics. Vast growth opportunities are therefore likely to present themselves, furthering the expansion of the global market for dilated cardiomyopathy therapeutics.
As dilated cardiomyopathy therapeutics lead to numerous side effects, patients might show less inclination towards their adoption, restricting growth. These therapeutics are believed to harm the kidney and liver during long term use, apart from other ailments such as stomach bleeding, convulsions, electrolyte imbalance, and weak pulse. Moreover, as implantable medical devices have successfully been eliminating the need for heart transplantations, patients might opt for these implants. The growing preference for minimally-invasive procedures has also been hindering the growth of the global market for dilated cardiomyopathy therapeutics market.
However, the growth of Asia Pacific and other emerging markets can create significant growth opportunities.
The information presented in this review is based on a Transparency Market Research report, titled, “Dilated Cardiomyopathy Therapeutics Market (Drug Class - Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers; Pipeline Drugs - ixCELL-DCM, ARRY-797, OR-1, MYDICAR, and CAP-1002) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2020.”
Key segments of the Dilated Cardiomyopathy market
Dilated Cardiomyopathy Therapeutics Market, by Drug Class
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin II receptor blockers (ARBs)
Dilated Cardiomyopathy Therapeutics Market, by Pipeline Drugs
Dilated Cardiomyopathy Therapeutics Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453